Wolf popper llp announces investigation on behalf of investors in y-mabs therapeutics, inc

New york, new york--(newsfile corp. - october 27, 2022) - wolf popper llp is investigating potential securities fraud claims on behalf of purchasers of y-mabs therapeutics, inc. ("y-mabs" or the "company") common stock (nasdaq: ymab).y-mabs is developing omburtamab, which is used to treat children with central nervous system/leptomeningeal cancer tumors.
YMAB Ratings Summary
YMAB Quant Ranking